Literature DB >> 21927500

Norepinephrine and serotonin metabolism and clinical response to combined imipramine and amitriptyline therapy in depression.

V Palaniappun1, V Ramachandran, O Somasundaram.   

Abstract

The present study was aimed to find out the alteration of NE and 5HT systems in depression, if so in the same direction or not and to find out the clinical response to combined therapy of Imipramine and Amitriptyline, both tricyclic antidepressants. The study group consisted of 39 depressives as defined by I. C. D. 9 and 17 normal controls. Hamilton Depression Rating Scale was used to assess the severity of depression initially and after clinical improvement with drugs. Urinary MHPG and CSF 5HIAA were estimated final] depressives as per the standard procedure. It was found that both urinary MHPG and CSF 5HIAA were lowered in depressives but when individual patients were analysed both were not altered in the same direction in a given individual. All the depressives showed equal therapautic response to combined administration of Imipramine and Amitripiyline.

Entities:  

Year:  1991        PMID: 21927500      PMCID: PMC2988307     

Source DB:  PubMed          Journal:  Indian J Psychiatry        ISSN: 0019-5545            Impact factor:   1.759


  13 in total

1.  Catecholamine metabolism, depressive illness, and drug response.

Authors:  J W Maas; J A Fawcett; H Dekirmenjian
Journal:  Arch Gen Psychiatry       Date:  1972-03

2.  Plasma concentration of amitriptyline and clinical response.

Authors:  R A Braithwaite; R Goulding; G Theano; J Bailey; A Coppen
Journal:  Lancet       Date:  1972-06-17       Impact factor: 79.321

3.  Plasma concentration of nortriptyline and clinical response in depressive illness.

Authors:  G D Burrows; B Davies; B A Scoggins
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

4.  Effect of intravenously administered probenecid in humans on the levels of 5-hydroxyindoleacetic acid, homovanillic acid and 3-methoxy-4-hydroxy-phenylglycol in cerebrospinal fluid.

Authors:  J Korf; H M van Praag; J B Sebens
Journal:  Biochem Pharmacol       Date:  1971-03       Impact factor: 5.858

Review 5.  The catecholamine hypothesis of affective disorders: a review of supporting evidence.

Authors:  J J Schildkraut
Journal:  Am J Psychiatry       Date:  1965-11       Impact factor: 18.112

6.  Antidepressant response to tricyclics and urinary MHPG in unipolar patients. Clinical response to imipramine or amitriptyline.

Authors:  H Beckmann; F K Goodwin
Journal:  Arch Gen Psychiatry       Date:  1975-01

7.  Amitriptyline plasma levels and clinical response in primary depression.

Authors:  D J Kupfer; I Hanin; D G Spiker; T Grau; P Coble
Journal:  Clin Pharmacol Ther       Date:  1977-12       Impact factor: 6.875

8.  "Serotonin depression"--a biochemical subgroup within the affective disorders?

Authors:  M Asberg; P Thorén; L Träskman; L Bertilsson; V Ringberger
Journal:  Science       Date:  1976-02-06       Impact factor: 47.728

9.  Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism.

Authors:  G Muscettola; F K Goodwin; W Z Potter; M M Claeys; S P Markey
Journal:  Arch Gen Psychiatry       Date:  1978-05

10.  MHPG, amitriptyline and affective disorders. A longitudinal study.

Authors:  E Sacchetti; E Smeraldi; M Cagnasso; P A Biondi; L Bellodi
Journal:  Int Pharmacopsychiatry       Date:  1976
View more
  2 in total

1.  Sex and race differences of cerebrospinal fluid metabolites in healthy individuals.

Authors:  Zackery W Reavis; Nikhil Mirjankar; Srikant Sarangi; Stephen H Boyle; Cynthia M Kuhn; Wayne R Matson; Michael A Babyak; Samantha A Matson; Ilene C Siegler; Rima Kaddurah-Daouk; Edward C Suarez; Redford B Williams; Katherine Grichnik; Mark Stafford-Smith; Anastasia Georgiades
Journal:  Metabolomics       Date:  2021-01-18       Impact factor: 4.290

2.  An overview of Indian research in depression.

Authors:  Sandeep Grover; Alakananda Dutt; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.